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Abstract
Background: Though peritoneal carcinomatosis reflects a late stage of colorectal cancer (CRC), only few patients
present with synchronous or metachronous liver metastases alongside their peritoneal carcinomatosis. It is
hypothesized that this phenomenon may be causally linked to molecular characteristics of the primary CRC. This
study used miRNA profiling of primary CRC tissue either metastasized to the liver, to the peritoneum or not
metastasized at all thus to identify miRNAs potentially associated with defining the site of metastatic spread in CRC.
Methods: Tissue of the primary tumor stemming from CRC patients diagnosed for either liver metastasis (LM; n = 10)
or peritoneal carcinomatosis (PER; n = 10) was analyzed in this study. Advanced CRC cases without metastasis
(M0; n = 3) were also included thus to select on those miRNAs most potentially associated with determining
metastatic spread in general. miRNA profiling of 754 different miRNAs was performed in each group. MiRNAs
being either differentially expressed comparing PER and LM or even triple differentially expressed (PER vs. LM
vs. M0) were identified. Differentially expressed miRNAs were further validated by in silico and functional
analysis.
Results: Comparative analysis identified 41 miRNAs to be differentially expressed comparing primary tumors
metastasized to the liver as opposed to those spread to the peritoneum. A set of 31 miRNAs was significantly
induced in primary tumors that spread to the peritoneum (PER), while the remaining 10 miRNAs were found
to be repressed. Out of these 41 miRNAs a number of 25 miRNAs was triple-differentially expressed (i.e.
differentially expressed comparing LM vs. PER vs. M0). The latter underwent in silico analysis. Finally, we
demonstrated that miR-31 down-regulated c-MET in DLD-1 colon cancer cells.
Conclusions: This study demonstrates that CRC primary tumors spread to the peritoneum vs. metastasized to
the liver display significantly different miRNA profiles. Larger patient cohorts will be needed to validate
whether determination of e.g. miR-31 may aid to predict the course of disease and whether this may help to
create individualized follow up or treatment protocols. To determine whether certain miRNAs may be
involved in regulating the metastatic potential of CRC, functional studies will be essential.
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Background
Metastatic spread is regarded a common feature of colo-
rectal cancer (CRC). About 20% of CRC cases present
with distant metastasis even at the time of primary diag-
nosis [1]. Approximately 60% of patients diagnosed for
advanced staged CRC is estimated to develop distant
metastasis within 5 years [2]. Liver metastases account
for about one third of all distant metastasis locations in
CRC [3]. Another common site of distant spread is the
peritoneum and about one out of four patients develops
peritoneal carcinomatosis during the course of disease
[4]. Importantly, although peritoneal carcinomatosis
mirrors a late stage of disease, only few patients present
with synchronous or metachronous hematogenous i.e.
liver metastases [5, 6]. Our recent work highlighted that
stem cell features of the primary tumor may direct the
way of metastasis [5, 7]. Those CRCs that will spread to
the liver display a prominent cancer stem cell-like
immuno-phenotype while those which will metastasize
to the peritoneum do not. We hypothesized that that
primary CRC cases developing solely PC but no
hematogenous metastases lack the stem cell features
needed for dissemination [5].
Factors related to this phenomenon by regulating
mRNA stability have not been identified yet. Though
miRNAs are considered to regulate metastatic potential
of various cancer cells, it remains unexplored whether
miRNA are involved in directing the metastatic route in
CRC. In general, miRNAs represent small RNAs that
majorly contribute to post-translational gene regulation.
Since miRNAs may be determined by a fully automated,
high throughput procedure they may become attractive
for routine diagnostic in the future. Further, since miR-
NAs may be counteracted by sequence specific antisense
oligo-nucleotides, they may evolve to be druggable tar-
gets. We used an expression platform covering a set of
highly characterized miRNAs as well as several of the
more recently discovered miRNAs along with the star
miR* sequences. miRNA profiling of primary tumor tis-
sue was employed to identify those miRNAs potentially
being associated with determining the location of syn-
chronic or metachronic metastatic spread in CRC.
Methods
Patients
Patients diagnosed for CRC (n = 23) between 1988 and
2012 were included in the study. Patients were selected
from a study panel published earlier [5] and were further
characterized within the current analysis. All patients
underwent surgical resection of their CRC at the Depart-
ment of General, Visceral, Transplantation and Vascular
Surgery Surgery, University Hospital Munich (Munich,
Germany). Formalin-fixed-paraffin-embedded tissue of
the primary tumor was used for all the analysis
described. CRC tissue underwent routine histopatho-
logical processing and examination. FFPE sample were
stored under standardized conditions.
Patients were classified as either pT3 (15/23) or pT4
(8/23). Most patients were graded as high (14/23) at ini-
tial diagnosis. About half of all cases were male (12/23)
and were diagnosed CRC that had already spread to ab-
dominal lymph nodes (18/23). Mean age of the cohort
was 65.8 ± 12.5 years.
Patients were retrospectively grouped into three groups
according to metastasis location: group M0: CRC without
metastasis formation during follow up period (n = 3),
group LM: CRC metastasized to the liver either at initial
diagnosis or during follow up without peritoneal carcin-
omatosis (n = 10), group PER: CRC spread to the periton-
eum either at initial diagnosis or during follow up without
liver metastasis (n = 10).
Study design
Patient data and tumor samples were retrieved from a
patient panel that was collected prospectively and that
has been published earlier by our group [5]. Samples
were further characterized in the current analysis. The
outcome assessed was metastasis formation after a mean
follow up of 9.6 ± 2.2 years. During follow up 14 deaths
were observed and mean overall survival was 8.4 ±
2.1 years.
Assay methods
RNA isolation, processing and multiplex qRT-PCR
RNA isolation was performed on freshly sliced FFPE tis-
sue samples. All preparation steps were performed under
sterile, RNAse and DNAse free conditions. First, samples
were dewaxed by xylene and washed in absolute ethanol.
Representative tumor areas were extracted by micro-
scope assisted microdissection. Dissection was super-
vised by an experienced senior pathologist (JN). Tumor
stroma or other connective tissue was strictly excluded
during sample preparation. A serial slide of each sample
was H&E stained thus to ensure that areas of necrotic
tumor, lymphocyte rich regions or areas directly adjacent
to the invasive front do not get included. RNA was
transferred into 1.5 ml tubes and further processed by
applying the RecoverAll™ Total Nucleic Acid Isolation
Kit for FFPE (Applied Biosystems, Carlsbad, CA) as per
manufacturer’s recommendation.
Amount and quality of total RNA was quantified by a
NanoDrop (Thermo Fisher Scientific, Waltham, MA)
spectrophotometer. Those samples that had passed the
quality control (A260/280 > 2.0, clear single RNA peak)
were processed further. RNA concentrations were ad-
justed and equal amounts of RNA underwent cDNA
synthesis using either Panel A of B multiplex primer sets
(Applied Biosystems). cDNA synthesis was performed
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using the TaqMan® MicroRNA Reverse Transcription Kit
(Applied Biosystems) according to manufacturer’s proto-
col. Reverse transcription was run on a Mastercycler
gradient PCR machine (Eppendorf, Hamburg, Germany)
using the following PCR program: (2 min at 16 °C,
1 min at 42 °C, 1 sec at 50 °C) × 40 cycles followed by
5 min at 85 °C and cooling down to 4 °C. cDNAs were
pre-amplified using miRNA specific primers as provided
with the Megaplex™ Primer Pools, Human Pools Set v3.0
(Applied Biosystems). Pre-amplification was run on a
Mastercycler gradient PCR machine (Eppendorf ) using
the following PCR program: 10 min at 95 °C, 2 min at
55 °C, 2 min at 72 °C, 12 amplification cycles (15 s at
95 °C and 4 min at 60 °C) followed by 10 min at 99.9 °C
and cooling down to 4 °C.
Pre-amplified cDNA underwent single assay PCR for
RNU44 and hsa-miR185-5p to check for nucleic acid in-
tegrity. Finally, equal volumes of diluted, pre-amplified
cDNA, TaqMan® Universal PCR Master Mix, No
AmpErase® UNG and DEPC-water were loaded onto
TaqMan® Array Human MicroRNA A + B Cards Set
(Applied Biosystems). Three patient samples per group
(M0, LM, PER) were pooled. qRT-PCR run was per-
formed. MiRNAs being sufficiently expressed (i.e. cycle
threshold (CT) lower than 30 – as recommended by Ap-
plied Biosystems) were selected for comparative analysis.
RNU44, RNU48 and U6 snRNA were available as house-
keeping genes on all TLDA cards run. Ath-miR159a
served as a negative control.
The 2-ddCT method was used to quantify relative
miRNA expression (dCT (target sample) = CT (target
gene) – CT (housekeeping gene); ddCT (target sample)
= dCT (target sample) – dCT (reference sample)) [8]. A
set of 25 miRNAs was found to be triple differentially
expressed. Out of these 25 miRNAs three miRNAs were
selected for further analysis. First, the TLDA result was
validated by single PCR on three cases per group (that
had been measured on the TLDA card as well) and sec-
ond, expression of miR-215-5p, miR-31-5p and miR-
483-5p was analyzed in the whole study sample.
c-MET immunohistochemistry
c-MET immunohistochemistry (IHC) was performed on
LM and PER samples. The staining method employed had
been extensively validated and published by our group be-
fore [9]. In brief, c-MET (monoclonal anti-rabbit IgG,
clone EP1454Y, Epitomics, Burlingame, CA) was used at a
dilution of 1:150 and was detected using the Vectastain
Elite ABC kit (Vector, Burlingame, CA). DAB (Dako,
Glostrup, Denmark) served as a chromogen. System
(without primary antibody) and isotype (unspecific rabbit
IgG instead of the primary antibody) controls were per-
formed to control for unspecific staining. c-MET IHC
staining was determined using the H-score [9].
miR31 target gene validation
A human miRNA expression vector (pEZX-MR04) en-
coding either hsa-miR31 or a scrambled miRNA (both
from Gene Copoeia, Rockville, MD) was transfected into
DLD-1 cells by using Lipofectamine 2000 as a transfec-
tion system. Transfection was performed as per manu-
facturer’s recommendation using a 4:1 (transfection
reagent to plasmid) ratio. This ratio had been demon-
strated to achieve the highest transfection efficiency
(data not shown). Successful transfection of the trans-
gene and expression of miR-31 was monitored by Taq-
Man qRT-PCR. RNU44 served as a house-keeping gene.
Cell culture
DLD-1 colon cancer cells were purchased from ATCC
(LGC Standards GmbH, Wesel, Germany). Cell lines were
routinely checked for mycoplasma contamination and cell
line authentication and were found to be contamination
free. RPMI1640 containing 10% fetal calf serum was used
as a standard culture media. Neither antibiotics nor anti-
mycotics were added to culture media. Cells were pas-
saged twice a week. Only those cultures passaged at least
4 times and maximum up to 15 times were used for the
experiments.
Western blotting
Cells were seeded at a density of 75% per well and trans-
fection was performed 24 h after plating. Plates were incu-
bated 3 days at 37 °C in a humidified atmosphere and
were afterwards lysed in RIPA buffer containing protease
and phosphatase inhibitors. Lysates were cleared by cen-
trifugation at 15.000 rpm for 15 min at 4 °C. Total protein
concentrations of the supernatants were quantified and
adjusted. The Mini-Protean System (Biorad, Hercules,
CA) was used for polyacrylamide gel electrophoresis and
blotting. PVDF membranes were blocked in 5% milk pow-
der in TBS-0.1%Tween20 (TBST) for 1 h at room
temperature. Rabbit anti-cMet (Cell Signalling Technolo-
gies; diluted 1∶1000 in 5% milk powder-TBST) and rabbit
anti-GAPDH (Cell Signalling Technologies; diluted
1∶2000 in 5% milk powder-TBST) were used to incubate
membranes overnight. Membranes were processed using
a goat anti-rabbit IRDye® 680RD secondary antibody (Cell
Signalling Technologies) according to the manufacturer’s
instructions. Each experiment was repeated three times
under the same conditions achieving similar results. Blots
were quantified by employing the QuantityOne analysis
software (Biorad, Hercules, CA).
Statistical analysis methods
This study has been carried out according to the RE-
MARK (Reporting Recommendations for Tumor Marker
Prognostic Studies) criteria [10].
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The IBM statistics package SPSS (version 22) was used
to test data for statistical significance. Fisher’s exact test
and Student’s T test were used. Cell culture experiments
were repeated three times achieving similar results. Rep-
licates were performed independently and on different
passages of cells. A probability value of p < 0.05 was
deemed significant in all statistical tests.
Results
Study cohort
The current analysis selected 23 cases from a larger study
panel previously investigated by Neumann et al. [5] for
miRNA analysis. The current study sample (n = 23) was
characterized as follows: 10 patients diagnosed for CRC
metastasized to the liver either at initial diagnosis or dur-
ing follow up without peritoneal carcinomatosis (termed
‘LM’), 10 patients diagnosed for CRC spread to the peri-
toneum either at initial diagnosis or during follow up
without liver metastasis (termed ‘PER’) and finally three
CRC patients without metastasis formation during follow
up period (termed ‘M0’). Patient characteristics and
clinico-pathological variables according to WHO 2010
and TNM 2009 are summarized in Table 1. Gender, age,
grade, UICC stage and pN-Stage were not significantly dif-
ferent when cases with peritoneal carcinomatosis and
cases diagnosed for liver metastasis were compared. Those
tumors that had spread to the peritoneum were more
often assigned a pT4 grade than those which presented
with liver metastasis (7/10 vs. 0/10; p = 0.003).
A recent study from our group found that expression
of a stem cell classifier (βCathigh and CD44high and/or
CD133high) in primary CRC tissue predicts metastatic
spread to the liver [5], while absence of a stem cell like
immuno-phenotype was characteristic for CRC metasta-
sized to the peritoneum. Regarding the patient cohort
studied in the current work, the stem cell classifier
(βCathigh and CD44high and/or CD133high) was detected
in all those primary tumors that had set liver metastasis
either at time of diagnosis or during follow up (10/10).
The βCathigh and CD44high and/or CD133high-phenotype
was much rarer in cancers that presented alongside with
peritoneal carcinomatosis (PER group, 2/10, p = 0.001)
or had not set metastasis at all (M0 group; 0/3, p =
0.003) (Fig. 1).
Differential miRNA expression is associated with
metastatic spread of the primary CRC
MiRNA profiling was performed in primary colon can-
cer tissue of the study sample described above. Seven
hundred fifty-eight miRNAs (754 target miRNAs and 4
control RNAs) were analyzed (Fig. 2a). A total number
of 275 miRNAs (36.5%) was detected with a cycle
threshold (CT) lower than 30 and underwent further
analysis. Out of these 275 miRNAs a number of 41 miR-
NAs was identified to be differentially expressed (upreg-
ulated > 2.00-fold or downregulated < 0.500-fold) when
cases diagnosed with liver metastasis (LM) were com-
pared to those with peritoneal carcinomatosis (PER)
(Fig. 2b). A set of 31 miRNAs was significantly up-
regulated in the PER group, while 10 miRNAs were
found to be repressed in PER as compared to LM. The
miRNAs most significantly induced in PER were hsa-
miR-215-5p (17-fold), hsa-miR-31-3p (8.9-fold) and hsa-
miR-31-5p (5.4-fold). On the opposite, miR-483-5p
(0.04-fold), hsa-miR-1226-5p (0.29-fold) and hsa-miR-
296-5p (0.32-fold) were identified to be most obviously
repressed (Fig. 2b).
As a second step, we questioned how to further select on
those miRNAs potentially associated with peritoneal carcin-
omatosis and hence not only differentially expressed to LM
but also to M0 (abbreviated as PER to M0 in Fig. 2c). A set
of 27 miRNAs out of these 41 miRNAs identified previ-
ously was also found to be differentially expressed to M0
(Fig. 2c). hsa-miR-148a-3p (2.8-fold) and hsa-miR-215-5p
(3.6-fold) were upregulated when normalized to M0, while
the remaining 25 miRNAs were downregulated. The same
analysis was repeated regarding differential expression of
miRNAs in primary tumors metastasized to the liver (LM)
as compared to tumors that did not metastasize at all (M0)
(abbreviated as LM to M0 in Fig. 2d). A number of 36 miR-
NAs out of the 41 miRNAs described above (Fig. 2b) was
also found to be differentially expressed regarding LM to
M0 (Fig. 2d). Comparing LM to M0 only a single miRNA
(hsa-miR-483-5p) was upregulated (7.5-fold).
Taken together comparative analysis of PER vs. LM
(Fig. 2b), PER vs. M0 (Fig. 2c) and LM vs. M0 (Fig. 2d)
Table 1 Patients’ characteristics
LM PER M0
UICC
II 0 0 1
III 0 3 2
IV 10 7 0
Grading
G2 6 2 1
G3 4 8 2
pT
pT3 10 3 2
pT4 0 7 1
pN
pN0 3 0 2
pN + 7 10 1
sex
female 4 4 3
male 6 6 0
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revealed a set of 25 miRNAs to be triple-differentially
expressed, i.e. differentially among PER vs. LM, PER vs.
M0 and LM vs. M0 at the same time (Fig. 3a). These
miRNAs underwent in silico prediction analysis for their
association to colorectal cancer. According to the miR-
Cancer search algorithm [11–14] out of these 25 miR-
NAs being triple-differentially expressed a number of 16
miRNAs had been published to be linked to CRC in the
past. Out of these hsa-miR-215-5p, hsa-miR-31-5p as
well as hsa-miR-483-5p were further validated by single
PCR. Results obtained from TLDA cards were found to be
highly reproducible on single PCR level (Fig. 3b). hsa-
miR-215-5p, hsa-miR-31-5p and hsa-miR-483-5p were
then analyzed on the whole patient sample. Again, hsa-
miR-483-5p was repressed (0.51-fold) and both hsa-miR-
215-5p - (3.2-fold) and hsa-miR-31-5p (12-fold) were
induced (Fig. 3c). Statistical analysis comparing miRNA
expression on the whole sample only proved a significant
difference in case of hsa-miR-31-5p (p = 0.002; Fig. 3c).
miR-31 reduces c-MET expression in DLD-1 colon cancer
cells
We finally questioned whether hsa-miR-31-5p may func-
tionally interfere with metastasis formation. A literature
search revealed that hsa-miR-31-5p has been reported to
regulate genes involved in epithelial-to-mesenchymal
transition (EMT) [15–18], which is assumed to be a
major step within metastasis formation [19]. For in-
stance, Mitamura et al. reported miR-31 to directly tar-
get c-MET – a prominent mediator of EMT - in an
ovarian cancer model [15]. We thus selected c-MET to
test whether miR-31 is active in colon cancer cells.
DLD-1 colon cancer cells were transfected with pEZX-
MR04-miR-31 or pEZX-MR04-scr control vector. Target
gene expression was monitored by qRT-PCR 3, 7 and
14 h after transfection. Although we observed a net in-
crease in hsa-miR-31-5p expression at all the time points
analysed (3 h: 1.4-fold, 7 h: 5.8-fold, 12 h: 13-fold), stat-
istical testing proved significant induction for the 14 h
(p = 0.013) and the 7 h incubation period (p = 0.046)
(Fig. 4a). As a consequence, protein expression of
c-MET was measured 14 h after transfection and west-
ern blotting revealed significant downregulation of
c-MET (0.53-fold, p < 0.001; Fig. 4b).
Interestingly, regarding the patient panel expression of
hsa-miR-31-5p was inversely correlated (p = 0.011) with
presence of the stem cell classifier (βCathigh and
CD44high and/or CD133high). This is consistent with the
observation that the stem cell classifier has been de-
tected in all those cancers spread to the liver which at
the same time are expressing hsa-miR-31-5p on a low
level (Fig. 3c). On the other hand, PER cases were nega-
tive for the stem cell classifier while abundantly express-
ing hsa-mir-31-5p (Figs. 1d and 3c). Although c-MET
was regulated by miR-31 in DLD-1 colon cancer cells,
we could not identify a significant statistical association
of hsa-miR-31-5p expression and c-MET immunoposi-
tivity in the patients’ tumor tissue samples.
Discussion
Determination of metastatic spread in colorectal cancer
Several reports hypothesize that the risk of distant meta-
static spread may be predicted from the molecular pro-
file of the primary tumor [5, 20]. As a future perspective,
biomarkers identified in the primary tumor may aid to
forecast the course of disease i.e. location of metastatic
spread or whether metastasis will develop at all. Such at-
tempt may one day aid the clinician to plan individual-
ized follow up and potentially treatment protocols.
The probability of distant spread and poor outcome has
been linked to a 17-gene signature identified across differ-
ent types of human solid tumors [20]. Apart from predict-
ing the probability of metastatic spread in general,
molecular characteristics of the primary tumor may also
Fig. 1 beta Catenin (a), CD44 (b) and CD133 (c) immunopositivity served to sub-define primary tumors that had either spread to the peritoneum or to the
liver: Presence of a stem cell like phenotype as defined by beta Catenin (a), CD44 (b) and/or CD133 (c) high immunopositivity was found to characterize
primary tumors that spread to the liver, while absence of a stem cell like immuno-phenotype was characteristic for CRC metastasized to the peritoneum [5].
The current analysis selected 23 cases (n (LM) = 10, n (PER) = 10, n (M0) = 3) from the study panel previously investigated by Neumann et al. for further
characterization including miRNA analysis. Presence of a stem cell phenotype (βCathigh and CD44high and/or CD133high) in LM samples and absence of this
stem cell classifier in PER and M0 samples was highly reproducible in the sub-sample analyzed in the current study (d). The stem cell phenotype was much
rarer in PER (p= 0.001) and M0 (p= 0.003) than in LM samples. Significant changes are indicated by stars (*) in (d)
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forecast the site of metastasis formation [5, 21]. Neumann
et al. found that this phenomenon may be related to the
cancer stem cell phenotype of the primary tumor and that
those primary CRCs that lack stem cell like characteristics
may less often set liver metastasis during their clinical
course [5]. Potentially, this may be linked to the reduced po-
tential to disseminate via the blood stream. miRNAs have
been widely associated with cancer stem cell phenotype in
colorectal cancer mainly via regulating Wnt/B-catenin and
Notch signalling [22, 23]. For instance, miR-215, which is
among those miRNAs most often reported on in CSCs, has
been demonstrated to regulate CSC differentiation and che-
moresistance [23–26]. Search of miR-215 target genes re-
vealed that miR-215 may repress expression of cell cycle and
stemness genes while downregulation of miR-215 itself aug-
ments clonogenicity of colon cancer cells [24]. Interestingly,
we found miR-215 (hsa-miR-215-5p) to be repressed in
those primary tumors that metastasized to the liver as com-
pared to those that spread to the peritoneum. This may sup-
port the cancer stem cell like phenotype of colorectal cancer
metastasized to the liver as hypothesized in our former
study [5].
Fig. 2 miRNAs found to be differentially expressed. miRNA analysis and selection has been summarized schematically (a). miRNAs found to be
differentially expressed in tumors that had spread to the peritoneum as compared with those metastasized to the liver are displayed (b). These
miRNAs differentially expressed comparing LM and PER were then normalized to expression of the respective miRNA in M0 (c, d). Expression
levels of PER vs. M0 are shown in c, while expression levels of LM vs. M0 are shown in d. Grey charts represent significant changes whereas
squared charts stand for miRNAs not differentially expressed in the respective analysis (c, d). Expression ratios (2-ddCT) are displayed on a
log2 scale
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Fig. 3 Validation of selected miRNA expression patterns. 25 miRNAs were found to be triple differentially expressed and are displayed as heat
map (a). The heat map presents dCT data (dCT = CT (target gene) – CT (housekeeping gene)) with red indicating high (min. dCT value: - 2.4) and
blue indicating low (max. dCT value: 11.1) expression (3-color scale with white representing the midpoint). Three of these genes characterized as
triple differentially expressed were selected and analyzed by single TaqMan PCR assay PCR (b). Single PCR assays referred to in B were run on the
same samples that had been analyzed on the TLDA card (n (LM) = 3, n (PER) = 3, n (M0) = 3) thus to show that the data deriving from the TLDA
cards (referred to as “TLDA” in (b)) can be reproduced by running single assays (referred to as “single TaqMan assay” in (b)) on the cycler. Finally,
expression of hsa-miR-483-5p, hsa-miR-31-5p and hsa-miR-215-5p was analyzed in the whole study cohort (n (LM) = 10, n (PER) = 10, c). Error bars
represent standard error of mean. Significant changes in c (p < 0.05) are indicated with stars (*)
Fig. 4 Target gene regulation by miR-31. Expression of hsa-miR-31-5p in DLD-1 cells transfected with miR-31- or scr-control plasmid was monitored 3,
7 and 14 h after transfection by TaqMan-PCR (a). In addition, c-Met protein was determined 14 h after transfection by western blotting (b). Stars (*)
indicate significant changes (p < 0.05). Data derive from three different experiments achieving similar results
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In general, research on how miRNAs may be involved
in determining metastatic spread is on the increase [27].
However, previous studies compared colorectal cancer
tissue to normal non-cancer controls, drawing conclu-
sions on those miRNAs potentially involved in the biol-
ogy of CRC more generally [28–30]. To the best of our
knowledge, no study has been published on how miR-
NAs may influence the route of metastasis i.e. via the
blood stream into distant organs or via local spread into
the peritoneum. The current study identified a couple of
miRNAs to be differentially expressed among CRC sam-
ples that set metastasis into either liver or peritoneum
and stage-matched CRC cases that had not set any me-
tastasis at all. Several miRNAs identified in our analysis
had already proven to be differentially expressed in colo-
rectal cancer or may even be associated with clinico-
pathological parameters [25, 27, 28]. Hence, our data
may encourage functional analysis linking these miRNAs
to metastasis formation in in vitro and in vivo models.
Beyond hsa-miR-215-5p another two miRNAs were
validated on the whole patient panel. We selected hsa-
miR-483-5p, since it was strongest repressed miRNA
when expression of PER vs. LM was compared (Fig. 2b).
In contrast, hsa-miR-31-5p was chosen since it was the
second most obviously upregulated (regarding PER to
LM, Fig. 2b) miRNA. hsa-miR-31-5p underwent func-
tional analysis due to three reasons. When the analysis
was extended on the whole patient sample, differen-
tial expression only remained significant in case of
hsa-miR-31-5p (Fig. 3c). In addition, its star strand,
i.e. hsa-miR-31-3p, was also differentially expressed,
though failed to fulfil the criteria of triple differential
expression. Interestingly, up-regulation of both hsa-
miR-31-5p and its passenger strand hsa-miR-31-3p
was detected to be predictive in metastatic CRC pa-
tients treated with cetuximab - again suggesting this
miRNA to play a dominant role in metastatic CRC
[31]. Finally, miR-31 has been demonstrated to regu-
late cMet in ovarian cancer [15].
Of course, demonstrating inverse correlation of
miR-31 and c-MET at the exact time point (!) of
metastatic spread would be desirable. However, about
half of our primary tumor samples were resected
years before metastatic spread was diagnosed (i.e.
metachronous metastatic spread) and thus our sam-
ples did not mirror the state or time point of meta-
static spread. Since both metastasis formation and
miRNA mediated gene regulation are highly dynamic
processes, determination of c-MET at surgery of the
primary tumor, i.e. years before metastasis formation
may take place, seems not to be useful in terms of
analyzing whether miR-31 may regulate c-MET. This
may explain why there was no significant statistical
association of miR-31 and c-MET immunopositivity
in our tumor samples. An additional reason for this
is that initiation of metastasis formation is a complex
process and is supposed to be restricted to stem cells
or small sub-populations within the tumor [32–34].
Hypothetically assuming that miR-31 regulates c-MET
in cancer cells thus to participate in determining
metastatic spread, such a regulation process may only
take place in single clones that initiate metastasis
formation. The method used to determine c-MET
(= single marker IHC) in the current study was not
suited to discriminate metastasis initiating sub-clones
from the rest of the tumor cells. Hence, we quantified
c-MET throughout the whole tumor sample rather
than in specific sub-populations. This may methodic-
ally mask potential regulatory effects of miR-31 on
c-MET in certain sub-populations of tumor cells.
Hsa-miR-31-5p may act on epithelial-to-mesenchymal
transition by target gene regulation
Epithelial-to-mesenchymal transition (EMT) is
regarded to be a major step within metastasis forma-
tion [19]. miR-31 has been demonstrated to regulate
a number of genes closely associated with EMT and
metastasis formation. For instance, miR-31 was found
to inhibit SATB2 thereby supporting CRC cell growth,
invasion and metastasis formation [16]. On the other
hand, miR-31 overexpression has been shown to in-
hibit autophagy in cancer associated fibroblasts of
CRC thereby increasing apoptosis and reducing mi-
gration of co-cultured CRC cell lines [17]. Besides
this observation, autophagy rate may also serve as a
readout parameter for miR-31 activity – even in FFPE
samples. Induction of miR-31 inhibited integrin alpha
V and thus reduced metastatic potential of gastric
cancer cells [18]. In line with this, several authors
already highlighted miR-31 to directly target c-MET
(also known as scatter factor) - a prominent mediator
of EMT [15, 35, 36]. The current work was able to
reproduce this finding in colon cancer cells. Hence, it
may be hypothesized that repression of hsa-miR-31-
5p in LE samples may lead to up-regulation of
c-MET – at least at the time of initial metastatic
spread. Whether repression of c-MET by hsa-miR-31-
5p may also support EMT and whether this may aid
tumors cells to spread via the blood stream needs to
be determined. Finally, the current study demon-
strated induction of hsa-miR-31-5p in those primary
tumors that spread to the peritoneum - again sup-
porting the hypothesis that hsa-miR-31may regulate
metastatic potential of CRC.
Conclusion
This study found that miRNA expression of colorectal
cancer primary tumor tissue may predict the site of
Heublein et al. BMC Cancer  (2018) 18:201 Page 8 of 10
synchronous or metachronous metastatic spread. We
further identified hsa-miR-31-5p to be overexpressed
in those CRC cases that were diagnosed with periton-
eal carcinomatosis either at initial diagnosis or during
follow up. Interestingly, miR31 has been shown to re-
press expression of c-MET [15] - a kinase known to
play a pivotal role in epithelial-to-mesenchymal-tran-
sition and hematogenous metastatic spread [37, 38].
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